$1.84
-2.9%Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
STXS โข AMEX
| Stereotaxis, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-21.6M | -24M | -20.7M | -18.3M | -10.7M | -6.6M | -4.6M | 116.8K | -5.9M | -5.3M | -7.4M | -5.2M | -68.8M | -9.2M | -32M | -19.9M | -27.5M | -43.9M | -48.1M | -45.7M | |
1.6M | 969K | 595K | 429K | 106K | 126.2K | 122.7K | 579K | 753.7K | 566.9K | 620.1K | 713.6K | 1.2M | 1.6M | 1.8M | 1.9M | 2.2M | 4M | 1.6M | 1.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.2M | 3.8M | -3.6M | -890.2K | -3.5M | 47.5M | -8.2M | 33.4M | 1.7M | 3.2M | -3B | -5.6B | 0.0 | |
9.9M | 10.3M | 10.6M | 10.6M | 9.4M | 3.2M | 1.3M | 561K | 768.7K | 1.4M | 1.3M | 1.5M | 1.1M | 2.3M | 2.5M | 2M | 4.2M | 3B | 5.6B | 0.0 | |
2.2M | 1.8M | -256K | -25K | -1.8M | 2.3M | 2.3M | 24.7K | 100K | 674.1K | 222.7K | 240.6K | 8.3M | 3.1M | -37.8M | -4M | -2.9M | 5M | 7.5M | 4.3M | |
-5.6M | 2.5M | 612K | -1.1M | 135K | -2.5M | -3.8M | -1.7M | -4.2M | -259.2K | 3.6M | -2.8M | 4.4M | -1.7M | 564.7K | -639.5K | -1.6M | 6.2M | 3.3M | 829.4K | |
-13.7M | -8.5M | -9.1M | -8.4M | -2.9M | -3.5M | -4.6M | -2.5M | -4.7M | -6.6M | -2.5M | -9.1M | -6.3M | -12.1M | -31.6M | -18.9M | -22.3M | -28.7M | -35.7M | -39M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-93K | -34K | -366K | -2.4M | -1.4M | -70.9K | -29.5K | -265.5K | -81.6K | -410.2K | -153.2K | -123.9K | (0.0) | -130.7K | -1M | -715.8K | -1.5M | -1.7M | -4.7M | -2.3M | |
(0.0) | (108K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | -19.7M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -13.8M | -32.7M | |
0.0 | 0.0 | 20.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.7B | 6.7M | 29.1M | 18.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -153.2M | 0.0 | -130.7M | -130.7M | -1B | -715.8M | -6.7B | 2.2K | 100.6K | 10.1K | |
-93K | (74K) | (19.8M) | -22.1M | -1.4M | -70.9K | -29.5K | -265.5K | -81.6K | -410.2K | -153.2K | -123.9K | -130.7M | -130.7K | -1M | -715.8K | -1.5M | (5M) | (10.6M) | -16.4M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
14.8M | 297K | 81K | 220K | 547K | 15.2M | 24M | 57.1K | 41.1K | 23M | 964.5K | 2.9M | 21.3M | 9.1M | 239.6K | 16.2M | 27.9M | 19.7M | 21.9M | 67.9M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.2M | 0.0 | 0.0 | 0.0 | -13M | 40.4K | -142.4K | -9M | -3.1M | 11.1M | 8.1M | -3.9M | 17.3M | 5M | -1M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -43.5K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.9M | -100K | -100K | 0.0 | 0.0 | 21.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 134.7K | |
14.8M | 297K | 81K | 220K | 547K | 17.3M | 24M | 9.9M | -58.9K | 9.9M | 1M | 2.7M | 12.3M | 6.1M | 11.3M | 24.3M | 24M | 37M | 26.9M | 67M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 130.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
985K | -8.1M | 10.7M | -30.3M | -3.8M | 13.8M | 19.4M | 7.1M | -4.8M | 2.9M | -1.7M | -6.5M | 6M | -6.2M | -21.3M | 4.7M | 190.9K | 13.3M | 1.8M | 11.6M | |
12.4M | 20.6M | 9.9M | 40.1M | 43.9M | 30.2M | 10.8M | 3.7M | 8.5M | 5.6M | 7.3M | 13.8M | 7.8M | 14M | 35.2M | 30.5M | 30.4M | 17M | 15.2M | 3.6M | |
13.4M | 12.4M | 20.6M | 9.9M | 40.1M | 43.9M | 30.2M | 10.8M | 3.7M | 8.5M | 5.6M | 7.3M | 13.8M | 7.8M | 14M | 35.2M | 30.5M | 30.4M | 17M | 15.2M | |
-13.8M | -8.5M | -9.5M | -10.8M | -4.3M | -3.6M | -4.6M | -2.8M | -4.8M | -7M | -2.7M | -9.2M | -6.3M | -12.2M | -32.6M | -19.6M | -23.8M | -30.3M | -40.5M | -41.3M |
STXS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 15, 2026 | April 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | April 03, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 03, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | March 13, 2026 | March 13, 2026 | ย | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 11, 2025 | 2025 |
Continue your STXS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.